Activity of Cefepime in Combination with the novel ß-Lactamase inhibitor taniborbactam (VNRX-5133) against ESBL-producing isolates in in vitro checkerboard assays.

Conclusion The combination cefepime/taniborbactam demonstrated a potent activity against ESBL isolates restoring susceptibility of all Enterobacterales and 2/3 of P. aeruginosa isolates. PMID: 33431413 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33431413?dopt=Abstract

Source: Antimicrobial Agents and Chemotherapy - January 11, 2021 Category: Microbiology Authors: Kloezen W, Melchers RJ, Georgiou PC, Mouton JW, Meletiadis J Tags: Antimicrob Agents Chemother Source Type: research

More News: Chemotherapy | Gastroenteritis | Laboratory Medicine | Microbiology